Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab versus placebo in adults with heterozygous familial hypercholesterolemia inadequately controlled on lipid-lowering therapy
NL-OMON39858Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alirocumab in heterozygous familial hypercholesterolemia (HeFH), sponsored by Sanofi. Primary endpoint: LDL-C reduction at Week 24. Started Jan 2013; status: active, not recruiting.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NL-OMON39858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39858.